A new cancer drug has surprised researchers with the good performance it has made in an innovative study, which cured all members who participated in the trial.
A new cancer drug has surprised researchers with the good performance it has made in an innovative study, which cured virtually all members who participated in the trial.
Dostarlimab, a monoclonal antibody drug approved to treat endometrial cancer in the UK, exceeded expectations in a trial at the Memorial Sloan Kettering Cancer Center in New York.
One year after the end of the trial, each of the 18 patients with colorectal cancer had gone into remission, and doctors reportedly could not find any signs of cancer.
Dostarlimab costs about $ 11,000 (A $ 15,200) per dose of 500 mg in the US.
It is currently administered to about 100 patients with advanced endometrial cancer each year, with the goal of improving patients’ quality of life and preventing chemotherapy.
“Our message is: get tested for rectal cancer to see if the tumor is MMRd,” said Dr. Luis Diaz, lead author of a new article on the drug.
“No matter what stage the cancer is in, we have a rehearsal at the Sloan Kettering Memorial that can help you. And MSK has a special experience that really matters.”
“At the time of this report, no patient had received chemoradiotherapy or surgery, and no case of progression or recurrence had been reported during follow-up,” the researchers wrote in the study published in the New England Journal of Medicine.
“The results allowed us to skip both chemoradiotherapy and surgery and proceed with observation only.
“The implications for quality of life are substantial, especially among patients in whom standard treatment would affect the potential for having children.”
“There were many tears of happiness,” said Memorialist at the Sloan Kettering Cancer Center Memorial and co-author of the paper, Dr. Andrea Cercek.
“It’s incredibly gratifying to receive these happy tears and happy emails from patients in this study who finish treatment and realize, ‘My God, I can maintain all the normal functions of my body that I feared I might lose due to radiation or surgery.’ . ”
According to Cancer Australia, colorectal cancer, also known as bowel cancer, affects 100,000 Australians each year, with 15,000 Australians diagnosed with the disease in 2021.
People diagnosed with bowel cancer have a 70% chance of surviving five years.
It was the second most common cause of cancer death in 2019, with 5,255 deaths.
Originally published as the new innovative cancer drug “cures” all patients